Cover Image

Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial

Pulmonary intravascular thrombus formation has been widely observed in patients with respiratory failure, for example, in patients with SARS-CoV-2 infection (COVID-19). The aim of this study was to evaluate the efficacy/safety of alteplase thrombolysis in COVID-19 severe hypoxemic respiratory failur...

Full description

Saved in:
Bibliographic Details
Main Authors: Landoni, Giovanni (Author) , Chowdary, Pratima (Author) , Meziani, Ferhat (Author) , Creteur, Jacques (Author) , De Schryver, Nicolas (Author) , Motsch, Johann (Author) , Henrichmoeller, Ingrid (Author) , Pagès, Alain (Author) , Peter, Nuala (Author) , Danays, Thierry (Author) , Weigand, Markus A. (Author)
Format: Article (Journal)
Language:English
Published: 10 November 2024
In: Annals of intensive care
Year: 2024, Volume: 14, Issue: 1, Pages: 1-13
ISSN:2110-5820
DOI:10.1186/s13613-024-01386-z
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13613-024-01386-z
Verlag, kostenfrei, Volltext: https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01386-z
Get full text
Author Notes:Giovanni Landoni, Pratima Chowdary, Ferhat Meziani, Jacques Creteur, Nicolas De Schryver, Johann Motsch, Ingrid Henrichmoeller, Alain Pagès, Nuala Peter, Thierry Danays, and Markus A. Weigand, on behalf of the TRISTARDS Investigators
Description
Summary:Pulmonary intravascular thrombus formation has been widely observed in patients with respiratory failure, for example, in patients with SARS-CoV-2 infection (COVID-19). The aim of this study was to evaluate the efficacy/safety of alteplase thrombolysis in COVID-19 severe hypoxemic respiratory failure. In this multicenter, open-label study, patients were randomized to receive alteplase (low- or high-dose) over 5 days plus standard of care (SOC), or SOC alone. The primary endpoint was time to clinical improvement (≥ 2-point decrease on WHO Clinical Progression Scale, or hospital discharge) up to Day 28. Secondary endpoints included all-cause mortality at Day 28, treatment failure at Day 28 and change in arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) ratio at Day 6 versus baseline.
Item Description:Gesehen am 24.04.2025
Physical Description:Online Resource
ISSN:2110-5820
DOI:10.1186/s13613-024-01386-z

Similar Items